Drug intelligence / Profile preview

PUR2000

Development stage: Preclinical
Lead developer: Pulmatrix
Modality: Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

PUR2000 is an investigational inhaled drug candidate developed by Pulmatrix. It utilizes the company's proprietary iSPERSE™ dry powder delivery technology and has been studied for the treatment of chronic obstructive pulmonary disease (COPD). The formulation aims to improve drug delivery to the lungs, potentially enhancing efficacy and tolerability compared to existing therapies. As of now, its global highest R&D status is listed as pending, with no evidence of regulatory approval or commercial availability[1][4][7].

Brand names: PUR2000PUR-2000PUR 2000
Other names: PUR2000PUR-2000PUR 2000

Beyond the preview

Go deeper on PUR2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PUR2000.

Explore the full profile